What is tobacco use disorder?

Tobacco use disorder is the medical term for what most people call addiction to tobacco products, most commonly cigarettes. The condition is recognised because nicotine is among the most addictive substances; about two-thirds of people who try smoking develop daily use, and stopping is genuinely difficult for most regular smokers. Tobacco use is one of the leading preventable causes of death globally, with major contributions to lung disease, cardiovascular disease, and many cancers.

Why quitting is difficult. Nicotine binds to receptors in the brain that drive the release of dopamine, the chemical messenger involved in reward and motivation. With repeated use, the brain adapts to the regular nicotine input, and reduction or stopping produces withdrawal symptoms (cravings, irritability, restlessness, anxiety, low mood, sleep changes, increased appetite). The withdrawal lasts days to weeks; the cravings can come and go for much longer.

The combined approach works best. The most consistent finding is that combining pharmacotherapy with behavioural support produces substantially higher long-term quit rates than either alone. The combined approach is what professional tobacco-treatment programs deliver.

The pharmacotherapy options.

Nicotine replacement therapy provides nicotine through a non-inhaled route (patch, gum, lozenge, inhaler, nasal spray), reducing withdrawal symptoms while the person breaks the smoking behaviour. Combining a long-acting form (patch) with a short-acting form (gum or lozenge) is more effective than either alone.

Varenicline is an oral medicine that partially activates nicotine receptors. It reduces both withdrawal and the rewarding effects of smoking, making smoking less satisfying if the person slips. It is the most-effective single agent in most studies.

Bupropion is an oral medicine that affects dopamine and norepinephrine signalling. It reduces cravings and withdrawal and is particularly useful for people with comorbid depression.

Cytisine is an oral medicine related to varenicline that has expanded availability in many markets and offers comparable efficacy at lower cost.

The behavioural support options. Brief counselling from a clinician, telephone quitlines, telehealth-delivered structured counselling, and in-person group programs all add benefit on top of pharmacotherapy. Even brief interventions help.

Integrated care delivery. The most effective programs combine pharmacotherapy and behavioural support in one delivery channel. Primary-care embedded tobacco treatment, telehealth-delivered combined treatment, and employer-sponsored programs all reach patients who might never engage with a separate referral.

What to expect. Most people who quit successfully take several attempts. Each attempt provides learning that increases the chance the next one succeeds. The combination of medication, behavioural support, and persistence is what works for most people. If the first approach does not work, the right response is usually to try a different combination rather than to give up.